title: [Isosorbide-5-mononitrate (mono mac) in the prevention of bleeding from esophageal varicose veins in patients with liver cirrhosis].
abstract: Varicose esophageal veins bleeding is one of severe complications of hepatic cirrhosis. This complication is effectively managed with combination of beta-blockers with nitrates. Of the latter, optimal is isosorbite-5-mononitrate (mono mac). Its minimal risk of development of nitrate tolerance and pharmacokinetics does not depend on hepatic or renal function. A single dose of mono mac varies from 10 to 50 mg. The individual dose is selected by a fall in systolic blood pressure at rest (by 15-20 mm Hg) above 100 mm Hg. In appearance of serious headache nitrates are followed by beta-blockers monotherapy. It is inferred that isosorbite-5-mononitrate (mono mac) is effective in prophylaxis of hemorrhage from varicose veins of the esophagus both in beta-blockers and as monotherapy when beta-blockers are contraindicated.
authors: D T
authors: DT
authors: Abdurakhmanov
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D004359:Drug Therapy, Combination; D004932:Esophageal and Gastric Varices / Q000150:complications / Q000188:drug therapy* / Q000209:etiology; D006471:Gastrointestinal Hemorrhage / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D007548:Isosorbide Dinitrate / Q000031:analogs & derivatives / Q000627:therapeutic use*; D008103:Liver Cirrhosis / Q000150:complications*; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D000319:Adrenergic beta-Antagonists; D014665:Vasodilator Agents; D007548:Isosorbide Dinitrate; C030397:isosorbide-5-mononitrate